Claims
- 1. A method of in situ detecting localization and distribution of heparanase expression in a biological sample comprising the step of reacting the biological sample with a detectable anti-heparanase antibody, said anti-heparanase antibody being capable of binding a polypeptide as set forth in SEQ ID NO:2, and detecting the localization and distribution of said detectable anti-heparanase antibody.
- 2. The method of claim 1, wherein said biological sample is selected from the group consisting of cells and tissues.
- 3. The method of claim 1, wherein said biological sample is malignant.
- 4. The method of claim 3, wherein said malignancy is a solid tumor.
- 5. The method of claim 4, wherein said solid tumor is selected from the group consisting of carcinoma, adenocarcinoma, squameous cell carcinoma, teratocarcinoma, mesothelioma and melanoma.
- 6. The method of claim 4, wherein said solid tumor is a primary tumor, or a metastasis thereof, and is originated from an organ selected from the group consisting of liver, prostate, bladder, breast, ovary, cervix, colon, skin, intestine, stomach, uterus, and pancreas.
- 7. A method of detecting hcparanase protein in vitro in a body fluid of a patient comprising the steps of reacting said body fluid with an anti-heparanase antibody, said anti-heparanase antibody being capable of binding a polypeptide as set forth in SEQ ID NO:2, and monitoring said reaction.
- 8. The method of claim 7, wherein said body fluid is selected from the group consisting of plasma, urine, pleural effusions and saliva.
- 9. The method of claim 7, wherein said body fluid is of a patient suffering from a cancer.
- 10. The method of claim 7, wherein said anti-heparanase antibody is selected from the group consisting of a monoclonal antibody and a poly clonal antibody.
- 11. The method of claim 7, wherein reacting said body fluid with said anti-heparanase antibody is effected in solution.
- 12. The method of claim 7, wherein reacting said body fluid with said anti-heparanase antibody is effected on a substrate capable of adsorbing proteins present in said body fluid.
- 13. The method of claim 7, wherein said body fluid is of a patient suffering from breast carcinoma or metastatic breast carcinoma.
- 14. A method of detecting heparanase expression in a biological sample comprising the step of rcacting the biological sample with a detectable anti-heparanase antibody, said anti-heparanase antibody being capable of binding a polypeptide as set forth in SEQ ID NO:2, and detecting said detectable anti-heparanase antibody.
Parent Case Info
This is a divisional of U.S. patent application Ser. No. 09/322,977 filed Jun. 1, 1999, now U.S. Pat. No. 6,531,129, which is a divisional of U.S. patent application Ser. No. 09/071,739, filed May 1, 1998, now U.S. Pat. No. 6,171,545, which is a continuation-in-part of U.S. patent application Ser. No. 08/922,170, filed Sep. 2, 1997, now U.S. Pat. No. 5,968,822.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5362641 |
Fuks et al. |
Nov 1994 |
A |
6531129 |
Pecker et al. |
Mar 2003 |
B2 |
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9119197 |
Dec 1991 |
WO |
Non-Patent Literature Citations (7)
Entry |
Jin et al. (Int. J. Cancer (1990); 45: 1088-1095).* |
Kosir et al. (J. of Surgical Research 1997; 67: 98-105).* |
Nakajima et al. (J. of Cellular Biochemistry 1988; 36: 157-167).* |
Kosir et al. (Proceedings of the American Association for Cancer Research Annual Meeting, (1996) vol. 37, No. 0, pp. 495. Meeting Info.: 87th Annual Meeting of the American Association for Cancer Research Washington, D.C., USA Apr. 20-24, 1996).* |
Laskov et al. (International Journal of Cancer Jan. 1991; 47(1):92-8).* |
(Current Protocols in Immunology, Greene Publishing Associates and Wiley-Interscience, New York, 1991, pp. 2.1.1-2.1.2).* |
Campbell ,A. Monoclonal Antibody Technology, 1984, Elsevier Scientific Publications Co., Inc., NYC, pp. 1-33. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08/922170 |
Sep 1997 |
US |
Child |
09/071739 |
|
US |